Tylenol Trickles Back To Shelves As J&J Touts Consumer Turnaround
This article was originally published in The Tan Sheet
J&J CEO William Weldon says the firm has “turned the corner on a particularly difficult period” that featured extensive OTC product recalls and QC issues. Worldwide consumer product sales grew slightly in the fourth quarter and full 2011.
You may also be interested in...
Shareholder suit against Johnson & Johnson, including CFO Caruso, may proceed; Novartis pauses OTC production at Nebraska plant; Mead Johnson finds Enfamil powder clear of bacteria after stores pull the product; John Gay leaves NPA after two years as executive director and CEO; more news In Brief.
Johnson & Johnson expects innovation and marketing to restore consumer confidence in its OTC brands and drive a market-share rebound even as its U.S. sales continue to fall, dropping nearly 25% in its latest quarter.
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.